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Breast cancer is the most prevalent malignancy in women and metastatic breast cancer is a lead-ing cause of mortality, accounting for more than 
400 000 deaths annually worldwide.1 Even though an-
thracyclines and taxanes are the most active agents in 
breast cancer, treatment failure occurs in a substantial 
number of patients and median survival for metastat-
ic breast cancer remains 2 to 3 years.2-4 Resistance to 
antineoplastic agents, and in particular anthracyclines 
and taxanes, is a limiting factor in breast cancer therapy, 
either after metastatic or adjuvant treatment.3,5 With 
increasing use of anthracyclines and taxanes for early 
breast cancer, fewer effective options are available for 
patients with metastatic disease.3,4 Capecitabine is com-
monly used for the treatment of anthracycline- and/or 
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BACkgROunD AnD OBjECtIvEs: there is an unmet need for new combination treatments, especially for ag-
gressive, visceral, and high tumor burden metastatic breast cancer. Gemcitabine (Gem) has shown synergy with 
vinorelbine (Vrl) in preclinical models, and has a toxicity profile that is different from Vrl, another recently 
approved cytotoxic drug that seems to be effective in the treatment of breast cancer. 
MEthODs: We studied the efficacy and side effects of the Gem-Vrl combination as first-line chemotherapy in 
patients in an open-label, single arm, phase ii study in patients with locally advanced or metastatic breast cancer 
who had been previously treated with an anthracycline-based regimen in the adjuvant/neoadjuvant setting. 
REsuLts: of the 74 patients enrolled, 72 patients were evaluable for the primary treatment outcome (tumor 
response rates). four patients (6%) had a complete response and 26 patients (36%) had a partial response. 
nineteen patients (26%) had stable disease. the median time to disease progression was 37 weeks (range, 1-60 
weeks). median duration of response was 43 weeks (range, 8.6 to 55 weeks) and one-year survival was 77% 
(95% confidence interval, 64% to 86%). Grade 3-4 neutropenia without fever was reported in 10% of patients, 
thrombocytopenia in 1%, and febrile neutropenia in 11%. the most common clinical grade 3-4 toxicities were 
nausea (24%) and diarrhea and stomatitis (11% each). hospitalizations for adverse events mainly due to anemia, 
febrile neutropenia, septic shock and hepatic failure occured in 7%. 
COnCLusIOn: With an overall response rate of 42%, the Gem-Vrl combination had promising efficacy and 
good tolerability in metastatic breast cancer patients. 
taxane-pretreated metastatic breast cancer; however, 
objective response rates in phase II studies are only 20% 
to 28%.6,7 Therefore, there is an unmet need for new 
combination treatments, especially for aggressive, vis-
ceral and high tumor burden metastatic breast cancer. 
Gemcitabine (GEM) and vinorelbine (VRL) are two 
of the most recently approved cytotoxic drugs that seem 
to be effective in the treatment of several solid tumors 
including breast cancer. Single VRL chemotherapy has 
been administered as first- and second-line treatment 
in advanced breast cancer. The response rate as first-
line treatment has varied from 35% to 41%.8,9 As sec-
ond-line treatment, the overall response rate has been 
reported to be 16%, 27%, and 32%.8,10,11 When given in 
combination with other drugs, the second-line response 
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rate was higher.12,13 GEM is also active against breast 
cancer and has demonstrated single-agent response rates 
of approximately 20%.14 
A short pilot study of pretreated patients15 and a 
dose-finding study,16 both in patients with metastatic 
breast cancer, indicated promising results, although my-
elotoxicity was again the dominant side effect. Data on 
this combination in Egyptian patients is needed to assess 
it as a possible option for metastatic breast cancer pa-
tients pretreated with anthracyclines in this population 
of patients. 
PAtIEnts AnD MEthODs 
In an open label, single arm, non-randomized, unblinded 
phase II study in patients with locally advanced or meta-
static breast cancer who had been previously treated with 
one anthracycline with/without taxane-based regimen in 
the adjuvant/neoadjuvant or first-line metastatic setting, 
we studied the GEM-VRL combination in a 3-weekly 
schedule as first-line chemotherapy. The study was con-
ducted in five different oncology centers in Egypt. The 
primary objective of this study was to assess the efficacy 
of this combination by determining overall response rate. 
Secondary endpoints were the assessment of the toxicity 
of GEM in combination with VRL, as well as the time to 
disease progression and the survival at one year. 
Patients were included in the study only if they met all 
of the following criteria: histological or cytological diag-
nosis of breast carcinoma with evidence of unresectable, 
locally recurrent, or metastatic disease, or the presence 
of metastatic or local-regional recurrent disease, accord-
ing to the American Joint Committee on Cancer.17 Also 
required were uni-dimensionally measurable lesions 
with clearly defined margins that were clearly measur-
able by CT, chest x-ray or clinical examination, accord-
ing to RECIST criteria;18 no prior chemotherapy for 
metastatic or loco-regionally recurrent disease, or prior 
radiotherapy must have been completed at least 30 days 
before study entry; no concurrent hormonal therapy for 
metastatic breast cancer, a Karnofsky performance status 
of ≥70, an estimated life expectancy of at least 6 months, 
patient compliance and geographic proximity that al-
lowed for adequate follow-up, adequate organ function 
and signed informed consent from the patient or legal 
representative. Patients were excluded from the study 
if there was concurrent administration of other tumor 
therapy, pregnancy or breast-feeding, serious concomi-
tant disorders that would compromise the safety of the 
patient or compromise the patient’s ability to complete 
the study, a second primary malignancy that was clini-
cally detectable at the time of consideration for study 
enrollment, known or suspected brain metastasis, bone 
metastasis, pleural effusion or ascitis as the only sites of 
disease. 
GEM and VRL were given on days 1 and 8 every 
3 weeks. GEM was used at a dose of 1000 mg/m2 and 
VRL at 25 mg/m2. Every cycle, VRL was administered 
before GEM. Therapy was continued until there was 
evidence of progressive disease, the patient experienced 
unacceptable toxicity, the investigator decided that the 
patient should be discontinued, the patient requested 
discontinuation, or the patient received 6 cycles of the 
regimen. Any adverse event considered at least possibly 
related to treatment was defined as toxicity. 
After baseline evaluation, tumor status was assessed 
every other treatment cycle (approximately 6 weeks) 
while on study therapy and every 6 to 8 weeks during 
post-treatment follow-up until documented disease 
progression, death or 12 months after study enrollment, 
whichever occured first. Responses were assessed accord-
ing to Response Evaluation Criteria in Solid Tumors, 
version 1.0,17 and required confirmation at least 4 weeks 
after first evidence of response. 
Patients having documented disease progression were 
monitored for survival approximately every 2 months, 
until death or 12 months after study enrollment, which-
ever occured first. Patients were assessed for toxicity 
according to the National Cancer Institute Common 
Toxicity Criteria for Adverse Events, version 3.0.19
The Simon two-stage design was used to test the null 
hypothesis that the response rate was ≤40% versus the 
alternative hypothesis that the response rate was ≥55%.20 
Setting the type-I error rate at 0.04 and type-II error rate 
at 0.2, 35 patients were to be enrolled in the first stage 
of the trial. At the end of the first stage, if 15 or fewer 
responses were observed the trial was to be terminated. 
Otherwise, the trial was to go to a second stage, enroll-
ing an additional 45 evaluable patients. If at least 40 of a 
total of 80 evaluable patients responded, the treatment 
was then considered promising enough to warrant fur-
ther development. 
The primary endpoint of this study was tumor re-
sponse rate, which was defined as the number of patients 
with a confirmed response (complete response [CR] or 
partial response [PR] divided by the number of patients 
who qualified for tumor response analysis, i.e., the en-
rolled eligible patients with measurable disease and at 
least one dose of study therapy). These qualified patients 
were the basis of the duration of response analysis, one 
of the secondary endpoints. The other secondary end 
points of this study included time to disease progression 
and one-year survival rate, which were analyzed on the 
intent-to-treat basis including all enrolled eligible pa-
tients. The Kaplan-Meier method was used to estimate 
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the medians for time to disease progression, duration of 
response as well as the one-year survival rate.21 All pa-
tients who received at least one dose of study drug were 
evaluated for safety. 
REsuLts 
The 74 patients enrolled in this study had a median age 
of 45 years (Table 1). The majority were postmenopaus-
al. Seventy-two (97%) had a Karnofsky performance sta-
tus of 80% and above. Seventy-one patients (96%) were 
metastatic and only three patients had locally advanced 
disease (4%). All patients had previously received adju-
vant chemotherapy with anthracyclines for breast can-
cer. Thirty-seven patients (50%) had lung metastasis, 34 
(46%) had liver metastasis, and 44 (60%) had metastasis 
in three or more sites. 
The overall response rate was 42% (95% CI, 30% to 
54%) (n=30) in 72 evaluable patients, with a complete 
response in 4 patients (6%) and a partial response of in 
26 patients (36%) (Table 2). Stable disease was reported 
in 19 patients (26%) and progressive disease in 17 pa-
tients (24%). Disease progression was not assessable in 
6 (8%). The median duration of response was 43 weeks 
(range 8.6-55 weeks) (Figure 1).The median time to dis-
ease progression (Figure 2) was 36.7 weeks (range, 1-60 
weeks). The one-year survival rate was 77% (95% CI, 
64% to 86%). 
Toxicity data was available for all patients (Table 3). 
The most common grade 3-4 toxicities were vomiting 
(24%) diarrhea (11%) and stomatitis (11%) (Table 4). 
Serious clinical adverse events included 18 hospitaliza-
tions; 5 (7%) due to adverse events, 2 for platelet transfu-
sions and 14 for packed-RBC transfusions (Table 5). The 
mean (SD) number of cycles received for both GEM and 
VRL was 4.4 (1.8). Dose reductions occurred in 9.5% of 
cycles for both GEM and VRL. The dose reduction was 
mainly due to hematological toxicities for both drugs. 
None of the patients had more than one dose reduction. 
DIsCussIOn 
There is a clear requirement for alternative cytotoxic 
drugs or regimens with antitumour activity to treat pa-
tients with metastatic breast cancer who have already 
received anthracyclines. Few standard combination che-
motherapy treatments currently exist for this patient 
population, for which only a few drugs have shown activ-
ity as single agents. VRL has been tested in phase II trials 
in patients with previous treatment with anthracyclines 
with a reported response rate of 25% and a median time 
to disease progression of 3 months.22,23 GEM has shown 
modest activity (response rate 13%) as a single agent in 
metastatic breast cancer, especially when used as second-
Table 1. Patients characteristics at baseline.
   Patients Characteristics at Baseline, n (%) Total (n=74)
   age (years)
     median 45
     range 26-65
   Performance status (Karnofsky)
      70% 2 (3)
      80% 38 (51)
      90% 25 (34)
      100% 9 (12)
   menopausal status
      Postmenopausal 41 (55)
      Premenopausal 33 (45)
   Stage at initial presentation
      i 0 (0)
      ii 23(31)
      iiia 26 (35)
      iiib 11 (15)
      iiic 6 (8)
      iv 7 (10)
      Unspecified 1 (1)
   Histology
      Ductal 68 (92)
      lobular 3 (4)
      Other 3 (4)
   Stage at study entry
      metastatic 71 (96)
      local recurrence 3 (4)
   measurable disease sites
       lung 37 (50)
       liver 34 (46)
       bone 14 (19)
       lymph nodes 38 (51)
       breast 11 (15)
   Prior therapy
       Surgery 67 (91)
       Chemotherapy 74 (100)
       anthracyclines 73 (99%)
       adjuvant hormonal 15 (20)
       radiotherapy 56 (76)
   measurable lesions at baseline/patient
       One site 9 (12)
       Two sites 21 (28)
       Three or more sites 44 (60)
er; estrogen receptors,  Pr; Progesteron receptors
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line or third-line treatment.24 However, GEM in combi-
nation with paclitaxel has been approved for the first-line 
treatment of metastatic breast cancer, after a large multi-
center trial reported that the combination was more ef-
fective than single-agent paclitaxel in terms of response 
rate, time to disease progression, and overall survival.25 
Because of the activity of VRL and GEM as single 
agents in pretreated metastatic breast cancer, and the 
lack of overlapping non-hematological toxic effects, 
phase II studies were initiated to test the activity of the 
combination of these two drugs, where the response 
rates ranged from 36% to 80% with an average of 60%.26-
40 There was also one phase III trial of the combina-
tion of GEM-VRL versus VRL alone, which reported 
a response rate for the combination of 36% versus 25 % 
for VRL alone. In this trial the median progression-free 
survival for the combination was 6.3 months versus 4.1 
months for VRL alone (P=.001). The main grade 3-4 
toxicities reported in this phase III trial were neutro-
penia (65%), febrile neutropenia (10%) and thrombo-
cytopenia (11%).41 The main reported toxicities in the 
various trials reported in the literature were grade 3-4 
neutropenia ranging from 12%38 to 42%,31 grade 3-4 
anemia ranging from 1%33 to 17%25 and thrombocy-
topenia grade 3-4 ranging from 1%32 to 18%.30 Other 
frequently reported clinical toxicities were nausea, diar-
rhea and asthenia.26-40 The response rates and disease 
progression in our study are consistent with the results 
of previously reported in phase II and III studies.The 
median duration of response and median time to dis-
ease progression are similar to the reported phase III 
trial where the progression free survival was 6.3 months 
in the combination arm versus 4.1 months in the single 
agent VRL arm.41 Other phase II studies reported time 
to disease progression between 3 and 6.8 months. 
The toxic effects of the combination were manage-
able and consisted mainly of grade 3-4 febrile neutro-
penia and clinical toxicities of nausea, diarrhea and 
stomatitis. The most commonly reported toxicities 
in previously reported trials were neutropenia, febrile 
Table 2. response rates in 72 evaluable patients with metastatic 
breast cancer.
 Total  (n= 72)
   Confirmed responsea 30 (42)
   95% Confidence intervalb 30-54
   Complete response 4 (6)
   Partial response 26 (36)
   Stable disease 19 (26)
   Progressive disease 17 (24)
   not assessable   6 (8)
values are number of patients (percentages)
aComplete and partial response, bCi : Confidence interval
Table 3. Common laboratory toxicities.
   Laboratory toxicities
Grade 1 and 2 Grade 3 and 4
n (%T) n (%T)
   Febrile neutropenia 0 (0) 8 (11)
   neutropenia 29 (39) 7 (10)
   leukopenia 24 (32) 4 (5)
   anemia 39 (53) 1 (1.4)
   Thrombocytopenia 4 (5) 1 (1.4)
   neutropenia with infection 0 (0) 1 (1.4)
T: Total
Table 4. Common clinical toxicities.
   Clinical toxicities
Grade 1 and 2 Grade 3 and 4
n (%T) n (%T)
   nausea 18 (24) 2 (3)
   vomiting 12 (16) 18 (24)
   anorexia 1 (1) 0 (0)
   asthenia 11 (15) 0 (0)
   Diarrhea 16 (22) 8 (11)
   alopecia 18 (24) 0 (0)
   Fever 5(7) 0 (0)
   Stomatitis 8 (11) 8 (11)
   injection reaction 11 (15) 10 (14)
Table 5. Serious clinical adverse events related to study drug.
   Clinically significant adverse event n (%T)
   Hospitalization due to adverse event 5 (7)
   number of transfusions
      Platelets 2 (3)
      Packed rbCs 14 (19)
   Hepatic failure 1 (1.4)
   Septic shock 1 (1.4)
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Figure 2. Kaplan-meier curve of time to disease progression.
Figure 1. Kaplan-meier distribution of duration of overall response.
neutropenia, neausia and phlebitis.26-40 With an over-
all response rate of 42%, the GEM-VRL combination 
demonstrated promising efficacy and good tolerability 
in metastatic breast cancer patients. 
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